Roche said on Thursday that 2024 would see a return to sales growth as it is overcoming a slump in demand for its COVID-19 products and the sales decline of a trio of established cancer drugs is.
LONDON/FRANKFURT (Reuters) -Roche forecast a pick up in sales growth this year as it overcomes a slump in demand for its COVID-19 products and a decline in sales of a trio of established cancer drugs abates. Sales in 2023 rose 1% to 58.7 billion Swiss francs ($68 billion), slightly below analysts' average estimate of closer to 60 billion francs, according to LSEG data. CEO Thomas Schinecker told reporters it was a "significant achievement" that the company increased sales despite the sharp drop in demand for its COVID therapy and diagnostics kits.
Novo Nordisk on Wednesday forecast another year of double-digit sales and operating profit growth as it began easing restrictions on supply of its popular weight-loss drug Wegovy. The company, which has raced to increase output amid shortages of Wegovy, said it started gradually increasing the supply of the lower dose strength of the drug in the United States in January. Wegovy sales totalled 9.6 billion Danish crowns ($1.39 billion) between October and December, slightly lower than the previous quarter and a four-fold rise from the same period a year earlier.
Novo Nordisk will more
than double the amount of lower doses of its obesity drug Wegovy
in the United States compared with recent months, CEO Lars
Fruergaard Jorgensen said on Wednesday as the Danish.
COPENHAGEN/LONDON (Reuters) -Novo Nordisk will more than double supplies of lower doses of its obesity drug Wegovy in the United States compared with recent months, CEO Lars Fruergaard Jorgensen said on Wednesday, as the Danish drugmaker ramps up output of its popular therapy. Novo has been unable to meet runaway demand for Wegovy, and in May began limiting the number of U.S. patients who could start treatment by reducing supply of the lowest three doses of the appetite-suppressing weekly injection. While the Danish drugmaker said on Wednesday it was boosting supplies of lower strength Wegovy doses to the U.S. market, the company has not officially lifted that restriction.